Streptococcus pneumoniae Antibodies, IgG (23 Serotypes)
Ordering Recommendation

Evaluate the ability of a patient to produce antibody to pure polysaccharide vaccines (Pneumovax) or protein conjugated vaccines (Prevnar) after vaccination to rule out antibody deficiency.

Quantitative Multiplex Bead Assay
Tue, Fri
1-5 days
New York DOH Approval Status
This test is New York DOH approved.
Submit With Order
ARUP Consult®
Disease Topics
Specimen Required
Patient Preparation
Serum separator tube. Post-immunization specimen should be drawn 30 days after immunization and, if shipped separately, must be received within 60 days of pre-immunization specimen. 
Specimen Preparation
Separate serum from cells ASAP or within 2 hours of collection. Transfer 1.5 mL serum to an ARUP Standard Transport Tube. (Min: 0.25 mL) MARK SPECIMENS CLEARLY AS "PRE" OR "POST" SO SPECIMENS WILL BE SAVED AND TESTED SIMULTANEOUSLY. 
Storage/Transport Temperature
Refrigerated. "Pre" and "post" pneumococcal vaccine specimens can be submitted separately or together for testing. 
Unacceptable Conditions
Plasma or other body fluids. Contaminated, hemolyzed, or severely lipemic specimens. 
After separation from cells: Ambient: 48 hours; Refrigerated: 2 weeks; Frozen: 1 year (avoid repeated freeze/thaw cycles). 
Reference Interval
Interpretive Data
A pre- and post-vaccination comparison is required to adequately assess the humoral immune response to Prevnar 7 (P7), Prevnar 13 (P13), and/or Pneumovax 23 (PNX) Streptococcus pneumoniae vaccines. Pre-vaccination samples should be collected prior to vaccine administration. Post-vaccination samples should be obtained at least 4 weeks after immunization. Testing of post-vaccination samples alone will provide only general immune status of the individual to various pneumococcal serotypes.

In the case of pure polysaccharide vaccine, indication of immune system competence is further delineated as an adequate response to at least 50 percent of the serotypes in the vaccine challenge for those 2-5 years of age and to at least 70 percent of the serotypes in the vaccine challenge for those 6-65 years of age. Individual immune response may vary based on age, past exposure, immunocompetence, and pneumococcal serotype.

Responder Status Antibody Ratio
Non-Responder . . . . . . . . . . . . . . Less than 2-fold
Weak Responder . . . . . . . . . . . . . 2-fold to 4-fold
Good Responder . . . . . . . . . . . . . Greater than 4-fold

A response to 50-70 percent or more of the serotypes in the vaccine challenge is considered a normal humoral response1. Antibody concentration greater than 1.0 - 1.3 µg/mL is generally considered long-term protection2.

1. Daly TM, Pickering JW, Zhang X, Prince HE, Hill HR. Multilaboratory assessment of threshold versus fold-change algorithms for minimizing analytical variability in multiplexed pneumococcal IgG measurements. Clin Vaccine Immunol. 2014;21(7):982-8.
2. Daly TM, Hill HR. Use and Clinical Interpretation of Pneumococcal Antibody Measurements in the Evaluation of Humoral Immune Function. Clin Vaccine Immunol. 2015;22(2):148-152.

Statement B: Compliance Statement B: For laboratory developed tests not using a RUO kit, and for FDA approved, cleared or 510(k) exempt assays with alterations. This test was developed and its performance characteristics determined by ARUP Laboratories. The U. S. Food and Drug Administration has not approved or cleared this test; however, FDA clearance or approval is not currently required for clinical use. The results are not intended to be used as the sole means for clinical diagnosis or patient management decisions.

Hotline History
Component Test Code*Component Chart NameLOINC
0050706Pneumo serotype 1 IgG (P13,PNX)85954-6
0050708Pneumo serotype 4 IgG (P7,P13,PNX)86107-0
0050709Pneumo serotype 5 IgG (P13,PNX)86130-2
0050713Pneumo serotype 6B IgG (P7,P13,PNX)27118-9
0050715Pneumo serotype 3 IgG (P13,PNX)86080-9
0050716Pneumo serotype 7F IgG (P13,PNX)25296-5
0050717Pneumo serotype 9N IgG (PNX)86169-0
0050718Pneumo serotype 14 IgG (P7,P13,PNX)85991-8
0050719Pneumo Serotype Interpretation42771-6
0050721Pneumo serotype 8 IgG (PNX)86147-6
0050722Pneumo serotype 9V IgG (P7,P13,PNX)30153-1
0050723Pneumo serotype 12F IgG (PNX)85977-7
0050724Pneumo serotype 18C IgG (P7,P13,PNX)27395-3
0050726Pneumo serotype 19F IgG (P7,P13,PNX)86024-7
0050727Pneumo serotype 23F IgG (P7,P13,PNX)86064-3
2005780Pneumo serotype 2 IgG (PNX)86039-5
2005781Pneumo serotype 10A IgG (PNX)86098-1
2005782Pneumo serotype 11A IgG (PNX)86122-9
2005783Pneumo serotype 15B IgG (PNX)40973-0
2005784Pneumo serotype 17F IgG (PNX)86009-8
2005785Pneumo serotype 19A IgG (P13,PNX)40974-8
2005786Pneumo serotype 20 IgG (PNX)86045-2
2005787Pneumo serotype 22F IgG (PNX)86052-8
2005788Pneumo serotype 33F IgG (PNX)40969-8
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, please view this test within the Laboratory Test Directory found at
  • pneumo conjugate vaccine
  • Pneumo polysaccharide vaccine
  • S. Pneumoniae Vaccine
  • Strep Antibodies 23 serotypes
  • Strep Pneumo Antibodies
  • Strep Pneumoniae Antibody
  • Strep Vaccine